Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna, Ipsen Ink RNAi Drug-Discovery Deal

Premium

Dicerna Pharmaceuticals said this week that it has signed a deal with French biotechnology firm Ipsen to develop RNAi-based therapeutics in the areas of oncology and endocrinology.

Under the terms of the deal, the companies will combine Dicerna's Dicer-substrate technology with Ipsen's peptide-based targeting vectors, which they said will allow cell-specific, intracellular delivery of the RNAi molecules.

Although the arrangement is focused on drug discovery, "Dicerna and Ipsen may collaborate further to move the programs discovered under this partnership into development and eventual commercialization," they noted.

Specific terms of the arrangement were not disclosed.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.